Cancer stem cells and human liver cancer

癌症干细胞与人类肝癌

基本信息

项目摘要

The existence of tumor-initiating cancer stem cells (CSC) has been shown in a variety of solid tumors (e.g., breast, prostate, glioblastoma, liver). However, these CSC have highly variable antigenic and functional properties even when derived from the same tumor. These observations highlight a cardinal problem in CSC biology, namely, the heterogeneity of the CSC. Different mechanisms could explain the origin and heterogeneity of CSC such as (i) differentiation arrest (stem cells), (ii) dedifferentiation (mature cells) and (iii) transdifferentiation (bone marrow stem cells). It is conceivable that all 3 mechanisms may be corrupted by oncogenic events, resulting in an assortment of CSC and explaining their heterogeneity. Defining and characterizing this heterogeneity is of vital importance for understanding CSC biology, and for effective therapeutic translation. Our most recent results in this project include: (1)Human hepatocellular carcinoma (HCC) is a heterogeneous disease of distinct clinical subgroups. A principal source of tumor heterogeneity may be cell type of origin, which in liver includes hepatocyte or adult stem/progenitor cells. To address this issue, we investigated the molecular mechanisms underlying the fate of the enzyme-altered preneoplastic lesions in the resistant hepatocyte (RH) model. Sixty samples classified as focal lesions, adenoma, and early and advanced HCCs were microdissected after morphological and immunohistochemical evaluation and subjected to global gene expression profiling. The analysis of progression of the persistent glutathione S-transferase (GSTP)(+) focal lesions to fully developed HCC showed that approximately 50% of persistent nodules and all HCCs expressed cytokeratin 19 (CK19), whereas 14% of remodeling nodules were CK19(+). Unsupervised hierarchical clustering of the expression profiles also grouped the samples according to CK19 expression. Furthermore, supervised analysis using the differentially expressed genes in each cluster combined with gene connectivity tools identified 1308 unique genes and a predominance of the AP-1/JUN network in the CK19(+) lesions. In contrast, the CK19-negative cluster exhibited only limited molecular changes (156 differentially expressed genes versus normal liver) consistent with remodeling toward differentiated phenotype. Finally, comparative functional genomics showed a stringent clustering of CK19(+) early lesions and advanced HCCs with human HCCs characterized by poor prognosis. Furthermore, the CK19-associated gene expression signature accurately predicted patient survival (P < 0.009) and tumor recurrence (P < 0.006). Conclusion: Our data establish CK19 as a prognostic marker of early neoplastic lesions and strongly suggest the progenitor derivation of HCC in the rat RH model. The capacity of CK19-associated gene signatures to stratify HCC patients according to clinical prognosis indicates the usefulness of the RH model for studies of stem/progenitor-derived HCC.(2)The ability to retain DNA labels over time is a property proposed to be associated with adult stem cells. Recently, label retaining cells (LRC) were indentified in cancer. LRC were suggested to be the result of either slow-cycling or asymmetric-cell-division with nonrandom-chromosomal-cosegregation (ACD-NRCC). ACD-NRCC is proposed to segregate the older template DNA strands into daughter stem cells and newly synthesized DNA into daughter cells destined for differentiation. The existence of cells undergoing ACD-NRCC and the stem-like nature of LRC remain controversial. Currently, to detect LRC and ACD-NRCC, cells need to undergo fixation. Therefore, testing the stem-cell nature and other functional traits of LRC and cells undergoing ACD-NRCC has been limited. Here, we show a method for labeling DNA with single and dual-color nucleotides in live human liver cancer cells avoiding the need for fixation. We describe a novel methodology for both the isolation of live LRC and cells undergoing ACD-NRCC via fluorescence-activated cell sorting with confocal microscopy validation. This has the potential to be a powerful adjunct to stem-cell and cancer research.(3)Current evidence suggests that hepatocellular carcinoma (HCC), the most common adult primary liver cancer, comprises biologically distinct subgroups including the recently identified hepatic progenitor cell- and cholangiocarcinoma (CC)-like subtypes. These observations support the notion that HCCs can be derived from different cells within the lineage from adult liver stem cell to hepatocyte. We addressed two questions: (1) does the transforming potential of oncogenes depend on the stage of hepatocytic differentiation and (2) is the tumor phenotype determined by the stage of differentiation at which transformation occurs. Fetal (ED16.5) hepatocytes were purified by magnetic sorting and adult (3-month) hepatocytes were isolated by collagenase perfusion from C57BL/6 mice. Cells were transduced with lentiviral vectors carrying oncogenic H-Ras and SV40 large T (LT) together with GFP and mCherry fluorescent reporters. Double positive cells were sorted and injected into the spleen of NOD/SCID mice. Tumors larger than 3 mm derived from the transduced fetal (n=20) and adult hepatocytes (n=20) were macrodissected and subjected to histopathology evaluation, immunohistochemistry and transcriptome profiling. Cancer stem cell traits were examined by FACS analysis of lineage specific and cancer stem cell associated markers, side population and tumor sphere formation assays using cell lines established from fetal and adult hepatocyte-derived tumors. Both fetal and adult hepatocytes co-transduced with oncogenic H-Ras/SV40LT produced liver tumors with similar growth characteristics and gave rise to lung metastases with 80% (8/10) and 63% (5/8) frequency, respectively. Histologically, fetal and adult hepatocyte-derived tumors were moderately-poorly differentiated HCCs with CC-like phenotype. All tumor cell lines were 100% positive for CK18, CK19, EpCam, A6, CD44, CD49f and CD29 and contained SP fraction (1-2%) as measured by FACS analysis regardless of the cell origin. CD133 was expressed at lower and variable levels in fetal (26.07.2%) and adult (46.19.1%) tumor cell lines. Both fetal and adult tumor cells possessed a sphere forming capacity which was maintained within 5 sphere generations. Unsupervised hierarchical clustering separated the fetal and adult tumors after log2 transformation by using corresponding normal samples as reference. Our results suggest that the activation of certain oncogenic pathways may have more significant effect on the tumor phenotype than the stage of hepatocytic differentiation at which the transformation occurs. Oncogenic H-Ras and SV40LT are capable of inducing a cancer stem cell-like state in mature hepatocytes that displays characteristics of hepatic stem cells.

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Snorri Thorgeirsson其他文献

Snorri Thorgeirsson的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Snorri Thorgeirsson', 18)}}的其他基金

Comparative Functional Genomics
比较功能基因组学
  • 批准号:
    7966157
  • 财政年份:
  • 资助金额:
    $ 36.5万
  • 项目类别:
Cancer stem cells and human liver cancer
癌症干细胞与人类肝癌
  • 批准号:
    7965969
  • 财政年份:
  • 资助金额:
    $ 36.5万
  • 项目类别:
The role of c-met in liver biology
c-met 在肝脏生物学中的作用
  • 批准号:
    7965490
  • 财政年份:
  • 资助金额:
    $ 36.5万
  • 项目类别:
Cancer stem cells and human liver cancer
癌症干细胞与人类肝癌
  • 批准号:
    8937929
  • 财政年份:
  • 资助金额:
    $ 36.5万
  • 项目类别:
Cancer stem cells and human liver cancer
癌症干细胞与人类肝癌
  • 批准号:
    8552944
  • 财政年份:
  • 资助金额:
    $ 36.5万
  • 项目类别:
Cellular and Molecular Biology of the Hepatic Stem Cell Compartment
肝干细胞室的细胞和分子生物学
  • 批准号:
    7965036
  • 财政年份:
  • 资助金额:
    $ 36.5万
  • 项目类别:
Cellular and Molecular Biology of the Hepatic Stem Cell Compartment
肝干细胞室的细胞和分子生物学
  • 批准号:
    8552575
  • 财政年份:
  • 资助金额:
    $ 36.5万
  • 项目类别:
The role of c-met in liver biology
c-met 在肝脏生物学中的作用
  • 批准号:
    8349082
  • 财政年份:
  • 资助金额:
    $ 36.5万
  • 项目类别:
The role of c-met in liver biology
c-met 在肝脏生物学中的作用
  • 批准号:
    8552759
  • 财政年份:
  • 资助金额:
    $ 36.5万
  • 项目类别:
Validation of Therapeutic Target Genes in Human Liver Cancer
人类肝癌治疗靶基因的验证
  • 批准号:
    8937992
  • 财政年份:
  • 资助金额:
    $ 36.5万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 36.5万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 36.5万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 36.5万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 36.5万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 36.5万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 36.5万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 36.5万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 36.5万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 36.5万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 36.5万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了